Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 163

1.

Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial.

Bar-Or A, Calabresi PA, Arnold D, Markowitz C, Shafer S, Kasper LH, Waubant E, Gazda S, Fox RJ, Panzara M, Sarkar N, Agarwal S, Smith CH.

Ann Neurol. 2008 Mar;63(3):395-400. doi: 10.1002/ana.21363. Erratum in: Ann Neurol. 2008 Jun;63(6):803. Arnlod, Douglas [corrected to Arnold, Douglas].

PMID:
18383069
[PubMed - indexed for MEDLINE]
2.

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.

Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH; HERMES Trial Group.

N Engl J Med. 2008 Feb 14;358(7):676-88. doi: 10.1056/NEJMoa0706383.

PMID:
18272891
[PubMed - indexed for MEDLINE]
Free Article
3.

Depletion of B lymphocytes from cerebral perivascular spaces by rituximab.

Martin Mdel P, Cravens PD, Winger R, Kieseier BC, Cepok S, Eagar TN, Zamvil SS, Weber MS, Frohman EM, Kleinschmidt-Demasters BK, Montine TJ, Hemmer B, Marra CM, Stüve O.

Arch Neurol. 2009 Aug;66(8):1016-20. doi: 10.1001/archneurol.2009.157. Erratum in: Arch Neurol. 2009 Nov;66(11):1384.

PMID:
19667224
[PubMed - indexed for MEDLINE]
4.

Long-term B-lymphocyte depletion with rituximab in patients with relapsing-remitting multiple sclerosis.

Stüve O, Leussink VI, Fröhlich R, Hemmer B, Hartung HP, Menge T, Kieseier BC.

Arch Neurol. 2009 Feb;66(2):259-61. doi: 10.1001/archneurol.2008.551.

PMID:
19204165
[PubMed - indexed for MEDLINE]
5.

Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis.

Stüve O, Cepok S, Elias B, Saleh A, Hartung HP, Hemmer B, Kieseier BC.

Arch Neurol. 2005 Oct;62(10):1620-3.

PMID:
16216948
[PubMed - indexed for MEDLINE]
6.

Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial.

Naismith RT, Piccio L, Lyons JA, Lauber J, Tutlam NT, Parks BJ, Trinkaus K, Song SK, Cross AH.

Neurology. 2010 Jun 8;74(23):1860-7. doi: 10.1212/WNL.0b013e3181e24373.

PMID:
20530322
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging.

Massacesi L, Parigi A, Barilaro A, Repice AM, Pellicanò G, Konze A, Siracusa G, Taiuti R, Amaducci L.

Arch Neurol. 2005 Dec;62(12):1843-7.

PMID:
16344342
[PubMed - indexed for MEDLINE]
8.

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.

Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW; AFFIRM Investigators.

N Engl J Med. 2006 Mar 2;354(9):899-910.

PMID:
16510744
[PubMed - indexed for MEDLINE]
Free Article
9.

Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.

Minagar A, Alexander JS, Schwendimann RN, Kelley RE, Gonzalez-Toledo E, Jimenez JJ, Mauro L, Jy W, Smith SJ.

Arch Neurol. 2008 Feb;65(2):199-204. Epub 2007 Dec 10.

PMID:
18071030
[PubMed - indexed for MEDLINE]
10.

Reduction in magnetic resonance imaging T2 burden of disease in patients with relapsing-remitting multiple sclerosis: analysis of 48-week data from the EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) study.

Traboulsee A, Al-Sabbagh A, Bennett R, Chang P, Li DK; EVIDENCE Study Group; UBC MS/MRI Research Group.

BMC Neurol. 2008 Apr 21;8:11. doi: 10.1186/1471-2377-8-11.

PMID:
18426595
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Paradoxically aggressive multiple sclerosis in the face of natalizumab therapy.

Berger JR.

Mult Scler. 2008 Jun;14(5):708-10. doi: 10.1177/1352458507087135.

PMID:
18566035
[PubMed - indexed for MEDLINE]
12.

Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review.

Castillo-Trivino T, Braithwaite D, Bacchetti P, Waubant E.

PLoS One. 2013 Jul 2;8(7):e66308. doi: 10.1371/journal.pone.0066308. Print 2013. Review.

PMID:
23843952
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

A controlled trial of natalizumab for relapsing multiple sclerosis.

Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA, Willmer-Hulme AJ, Dalton CM, Miszkiel KA, O'Connor PW; International Natalizumab Multiple Sclerosis Trial Group.

N Engl J Med. 2003 Jan 2;348(1):15-23.

PMID:
12510038
[PubMed - indexed for MEDLINE]
Free Article
14.

Regression of new gadolinium enhancing lesion activity in relapsing-remitting multiple sclerosis.

Zhao Y, Traboulsee A, Petkau AJ, Li D.

Neurology. 2008 Mar 25;70(13 Pt 2):1092-7. Epub 2007 Nov 14.

PMID:
18003938
[PubMed - indexed for MEDLINE]
15.

Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis.

Putzki N, Kollia K, Woods S, Igwe E, Diener HC, Limmroth V.

Eur J Neurol. 2009 Mar;16(3):424-6. doi: 10.1111/j.1468-1331.2008.02519.x.

PMID:
19187261
[PubMed - indexed for MEDLINE]
16.

Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.

Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.

Clin Ther. 2008 Jun;30(6):1102-12. doi: 10.1016/j.clinthera.2008.06.013.

PMID:
18640466
[PubMed - indexed for MEDLINE]
17.

Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results.

Rose JW, Burns JB, Bjorklund J, Klein J, Watt HE, Carlson NG.

Neurology. 2007 Aug 21;69(8):785-9.

PMID:
17709711
[PubMed - indexed for MEDLINE]
18.

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta.

Bielekova B, Richert N, Howard T, Blevins G, Markovic-Plese S, McCartin J, Frank JA, Würfel J, Ohayon J, Waldmann TA, McFarland HF, Martin R.

Proc Natl Acad Sci U S A. 2004 Jun 8;101(23):8705-8. Epub 2004 May 25. Erratum in: Proc Natl Acad Sci U S A. 2004 Dec 14;101(50):17565.

PMID:
15161974
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study.

Sorensen PS, Lisby S, Grove R, Derosier F, Shackelford S, Havrdova E, Drulovic J, Filippi M.

Neurology. 2014 Feb 18;82(7):573-81. doi: 10.1212/WNL.0000000000000125. Epub 2014 Jan 22.

PMID:
24453078
[PubMed - indexed for MEDLINE]
20.

Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.

Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, Hauser S, Waubant E, Vollmer T, Panitch H, Zhang J, Chin P, Smith CH; OLYMPUS trial group.

Ann Neurol. 2009 Oct;66(4):460-71. doi: 10.1002/ana.21867.

PMID:
19847908
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk